{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T22:02:40Z","timestamp":1780524160088,"version":"3.54.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T00:00:00Z","timestamp":1539734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T00:00:00Z","timestamp":1539734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study aimed to investigate the potential of an oral formulation (QV formulation) containing Quercetin and a Dipeptidyl Peptidase-4 Inhibitor (DPP-4 inhibitor), Vildagliptin, in improving metabolic homeostasis in type 1 diabetes model. Female albino Fischer rats were divided into four groups: untreated control animals (C), untreated diabetic animals (D), diabetic animals treated with QV formulation (DQV), and diabetic animals treated with insulin (DI). Diabetes was induced by injection of alloxan (135\u2009mg\u2009kg body mass)<jats:sup>\u22121<\/jats:sup> and confirmed by glycemic test. After the 30-day treatment period, biochemical parameters were analyzed in the pancreas, liver, and serum. Histopathological changes in pancreatic tissue were examined by Hematoxyline &amp; Eosin staining and the insulin content in the islet measured by immunohistochemistry with anti-insulin antibody. The glycogen content in the hepatocytes was quantified by Periodic Schiff Acid staining. The QV formulation reduced the glycemia, preserved the pancreatic architecture, increased insulin levels, furthermore ameliorated lipid profile and to promote higher survival rate of animals. Together, our data suggest that the QV formulation treatment was able to normalize metabolic homeostasis in type 1 diabetic rats.<\/jats:p>","DOI":"10.1038\/s41598-018-33727-x","type":"journal-article","created":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T13:54:30Z","timestamp":1539266070000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Oral formulation of DPP-4 inhibitor plus Quercetin improves metabolic homeostasis in type 1 diabetic rats"],"prefix":"10.1038","volume":"8","author":[{"given":"Pedro Henrique de A.","family":"Miranda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kissyla Christine Duarte","family":"Lacerda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina Morais","family":"Ara\u00fajo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mario","family":"Barichello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanderson Geraldo","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8904-332X","authenticated-orcid":false,"given":"Daniela Caldeira","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,17]]},"reference":[{"key":"33727_CR1","unstructured":"IDF. International Diabetes Federation: Diabetes Atlas. 8th edn, (International Federation Of Diabetes, 2017)."},{"key":"33727_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2337\/diacare.28.1.59","volume":"28","author":"TP GILMER","year":"2005","unstructured":"GILMER, T. P. et al. Predictors of health care costs in adults with diabetes. Diabetes Care 28, 59\u201364 (2005).","journal-title":"Diabetes Care"},{"key":"33727_CR3","doi-asserted-by":"publisher","first-page":"8260","DOI":"10.1073\/pnas.1505405112","volume":"112","author":"J Yu","year":"2015","unstructured":"Yu, J. et al. Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery. Proc Natl Acad Sci USA 112, 8260\u20138265, https:\/\/doi.org\/10.1073\/pnas.1505405112 (2015).","journal-title":"Proc Natl Acad Sci USA"},{"key":"33727_CR4","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/s2213-8587(16)00039-5","volume":"4","author":"CS Frandsen","year":"2016","unstructured":"Frandsen, C. S., Dejgaard, T. F. & Madsbad, S. Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus. Lancet Diabetes Endocrinol 4, 766\u2013780, https:\/\/doi.org\/10.1016\/s2213-8587(16)00039-5 (2016).","journal-title":"Lancet Diabetes Endocrinol"},{"key":"33727_CR5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/dom.12591","volume":"18","author":"M Nauck","year":"2016","unstructured":"Nauck, M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab 18, 203\u2013216, https:\/\/doi.org\/10.1111\/dom.12591 (2016).","journal-title":"Diabetes Obes Metab"},{"key":"33727_CR6","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.diabres.2016.08.022","volume":"121","author":"H Guo","year":"2016","unstructured":"Guo, H. et al. The efficacy and safety of DPP4 inhibitors in patients with type 1 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract 121, 184\u2013191, https:\/\/doi.org\/10.1016\/j.diabres.2016.08.022 (2016).","journal-title":"Diabetes Res Clin Pract"},{"key":"33727_CR7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.2174\/1389201015666141113124341","volume":"16","author":"PHA Miranda","year":"2015","unstructured":"Miranda, P. H. A. et al. Vildagliptin induces \u03b2-cell neogenesis and improves the lipid profile in a later phase of type 1 diabetes. Curr Pharm Biotechnol 16, 60\u201365 (2015).","journal-title":"Curr Pharm Biotechnol"},{"key":"33727_CR8","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.arcmed.2013.03.004","volume":"44","author":"DeL \u00c1vila","year":"2013","unstructured":"\u00c1vila, De. L. et al. Vildagliptin ameliorates oxidative stress and pancreatic beta cell destruction in type 1 diabetic rats. Arch Med Res 44, 194\u2013202, https:\/\/doi.org\/10.1016\/j.arcmed.2013.03.004 (2013).","journal-title":"Arch Med Res"},{"key":"33727_CR9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/dom.12005","volume":"15","author":"S Hamamoto","year":"2013","unstructured":"Hamamoto, S. et al. Vildagliptin preserves the mass and function of pancreatic \u03b2 cells via the developmental regulation and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Diabetes Obes Metab 15, 153\u2013163, https:\/\/doi.org\/10.1111\/dom.12005 (2013).","journal-title":"Diabetes Obes Metab"},{"key":"33727_CR10","doi-asserted-by":"publisher","first-page":"201","DOI":"10.4162\/nrp.2012.6.3.201","volume":"6","author":"SM Jeong","year":"2012","unstructured":"Jeong, S. M., Kang, M. J., Choi, H. N., Kim, J. H. & Kim, J. I. Quercetin ameliorates hyperglycemia and dyslipidemia and improves antioxidant status in type 2 diabetic db\/db mice. Nutr Res Pract 6, 201\u2013207, https:\/\/doi.org\/10.4162\/nrp.2012.6.3.201 (2012).","journal-title":"Nutr Res Pract"},{"key":"33727_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.phrs.2004.06.002","volume":"51","author":"O Coskun","year":"2005","unstructured":"Coskun, O., Kanter, M., Korkmaz, A. & Oter, S. Quercetin, a flavonoid antioxidant, prevents and protects streptozotocin-induced oxidative stress and beta-cell damage in rat pancreas. Pharmacol Res 51, 117\u2013123, https:\/\/doi.org\/10.1016\/j.phrs.2004.06.002 (2005).","journal-title":"Pharmacol Res"},{"key":"33727_CR12","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s13300-017-0299-7","volume":"8","author":"T Awata","year":"2017","unstructured":"Awata, T. et al. Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the Stage of Non-Insulin-Dependency: An Open-Label Randomized Controlled Pilot Trial (SPAN-S). Diabetes Ther 8, 1123\u20131134, https:\/\/doi.org\/10.1007\/s13300-017-0299-7 (2017).","journal-title":"Diabetes Ther"},{"key":"33727_CR13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4162\/nrp.2011.5.2.107","volume":"5","author":"JH Kim","year":"2011","unstructured":"Kim, J. H. et al. Quercetin attenuates fasting and postprandial hyperglycemia in animal models of diabetes mellitus. Nutr Res Pract 5, 107\u2013111, https:\/\/doi.org\/10.4162\/nrp.2011.5.2.107 (2011).","journal-title":"Nutr Res Pract"},{"key":"33727_CR14","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1111\/dme.13046","volume":"33","author":"PS George","year":"2016","unstructured":"George, P. S. & McCrimmon, R. J. Saxagliptin co-therapy in C-peptide negative Type 1 diabetes does not improve counter-regulatory responses to hypoglycaemia. Diabet Med 33, 1283\u20131290, https:\/\/doi.org\/10.1111\/dme.13046 (2016).","journal-title":"Diabet Med"},{"key":"33727_CR15","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1111\/j.1463-1326.2012.01610.x","volume":"14","author":"K Goo\u00dfen","year":"2012","unstructured":"Goo\u00dfen, K. & Gr\u00e4ber, S. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab 14, 1061\u20131072, https:\/\/doi.org\/10.1111\/j.1463-1326.2012.01610.x (2012).","journal-title":"Diabetes Obes Metab"},{"key":"33727_CR16","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1210\/jc.2012-2332","volume":"97","author":"J Farngren","year":"2012","unstructured":"Farngren, J., Persson, M., Schweizer, A., Foley, J. E. & Ahr\u00e9n, B. Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes. J Clin Endocrinol Metab 97, 3799\u20133806, https:\/\/doi.org\/10.1210\/jc.2012-2332 (2012).","journal-title":"J Clin Endocrinol Metab"},{"key":"33727_CR17","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s00125-015-3518-7","volume":"58","author":"S Malmgren","year":"2015","unstructured":"Malmgren, S. & Ahren, B. DPP-4 inhibition contributes to the prevention of hypoglycaemia through a GIP-glucagon counterregulatory axis in mice. Diabetologia 58, 1091\u20131099, https:\/\/doi.org\/10.1007\/s00125-015-3518-7 (2015).","journal-title":"Diabetologia"},{"key":"33727_CR18","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.2337\/db06-0080","volume":"55","author":"A Salehi","year":"2006","unstructured":"Salehi, A., Vieira, E. & Gylfe, E. Paradoxical stimulation of glucagon secretion by high glucose concentrations. Diabetes 55, 2318\u20132323, https:\/\/doi.org\/10.2337\/db06-0080 (2006).","journal-title":"Diabetes"},{"key":"33727_CR19","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1111\/j.1463-1326.2011.01414.x","volume":"13","author":"B Ahren","year":"2011","unstructured":"Ahren, B. et al. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab 13, 775\u2013783, https:\/\/doi.org\/10.1111\/j.1463-1326.2011.01414.x (2011).","journal-title":"Diabetes Obes Metab"},{"key":"33727_CR20","doi-asserted-by":"publisher","first-page":"5951","DOI":"10.1074\/jbc.M112.393769","volume":"288","author":"I Aukrust","year":"2013","unstructured":"Aukrust, I. et al. SUMOylation of pancreatic glucokinase regulates its cellular stability and activity. J Biol Chem 288, 5951\u20135962, https:\/\/doi.org\/10.1074\/jbc.M112.393769 (2013).","journal-title":"J Biol Chem"},{"key":"33727_CR21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1146\/annurev.bi.45.070176.001123","volume":"45","author":"HG Hers","year":"1976","unstructured":"Hers, H. G. The control of glycogen metabolism in the liver. Annu Rev Biochem 45, 167\u2013189, https:\/\/doi.org\/10.1146\/annurev.bi.45.070176.001123 (1976).","journal-title":"Annu Rev Biochem"},{"key":"33727_CR22","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s00125-007-0886-7","volume":"51","author":"S Lenzen","year":"2008","unstructured":"Lenzen, S. The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia 51, 216\u2013226, https:\/\/doi.org\/10.1007\/s00125-007-0886-7 (2008).","journal-title":"Diabetologia"},{"key":"33727_CR23","doi-asserted-by":"publisher","first-page":"817","DOI":"10.4239\/wjd.v5.i6.817","volume":"5","author":"GS Papaetis","year":"2014","unstructured":"Papaetis, G. S. Incretin-based therapies in prediabetes: Current evidence and future perspectives. World J Diabetes 5, 817\u2013834, https:\/\/doi.org\/10.4239\/wjd.v5.i6.817 (2014).","journal-title":"World J Diabetes"},{"key":"33727_CR24","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.2337\/db13-1440","volume":"63","author":"P Richards","year":"2014","unstructured":"Richards, P. et al. Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model. Diabetes 63, 1224\u20131233, https:\/\/doi.org\/10.2337\/db13-1440 (2014).","journal-title":"Diabetes"},{"key":"33727_CR25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.tem.2009.11.007","volume":"21","author":"E Tomas","year":"2010","unstructured":"Tomas, E. & Habener, J. F. Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis. Trends Endocrinol Metab 21, 59\u201367, https:\/\/doi.org\/10.1016\/j.tem.2009.11.007 (2010).","journal-title":"Trends Endocrinol Metab"},{"key":"33727_CR26","doi-asserted-by":"publisher","first-page":"4904","DOI":"10.1210\/endo.140.10.7158","volume":"140","author":"X Wang","year":"1999","unstructured":"Wang, X. et al. Glucagon-like peptide-1 regulates the beta cell transcription factor, PDX-1, in insulinoma cells. Endocrinology 140, 4904\u20134907, https:\/\/doi.org\/10.1210\/endo.140.10.7158 (1999).","journal-title":"Endocrinology"},{"key":"33727_CR27","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.bbrc.2013.09.110","volume":"440","author":"K Ishibashi","year":"2013","unstructured":"Ishibashi, K. et al. Beneficial effects of vildagliptin combined with miglitol on glucose tolerance and islet morphology in diet-controlled db\/db mice. Biochemical and biophysical research communications 440, 570\u2013575, https:\/\/doi.org\/10.1016\/j.bbrc.2013.09.110 (2013).","journal-title":"Biochemical and biophysical research communications"},{"key":"33727_CR28","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1096\/fj.06-6620com","volume":"21","author":"O Kwon","year":"2007","unstructured":"Kwon, O. et al. Inhibition of the intestinal glucose transporter GLUT2 by flavonoids. FASEB J 21, 366\u2013377, https:\/\/doi.org\/10.1096\/fj.06-6620com (2007).","journal-title":"FASEB J"},{"key":"33727_CR29","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1007\/s00125-002-0955-x","volume":"45","author":"M Elsner","year":"2002","unstructured":"Elsner, M., Tiedge, M., Guldbakke, B., Munday, R. & Lenzen, S. Importance of the GLUT2 glucose transporter for pancreatic beta cell toxicity of alloxan. Diabetologia 45, 1542\u20131549, https:\/\/doi.org\/10.1007\/s00125-002-0955-x (2002).","journal-title":"Diabetologia"},{"key":"33727_CR30","doi-asserted-by":"publisher","first-page":"798","DOI":"10.2337\/diacare.29.04.06.dc05-1433","volume":"29","author":"SS Soedamah-Muthu","year":"2006","unstructured":"Soedamah-Muthu, S. S. et al. High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database. Diabetes Care 29, 798\u2013804 (2006).","journal-title":"Diabetes Care"},{"key":"33727_CR31","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1039\/c4fo01178c","volume":"6","author":"K Kawabata","year":"2015","unstructured":"Kawabata, K., Mukai, R. & Ishisaka, A. Quercetin and related polyphenols: new insights and implications for their bioactivity and bioavailability. Food Funct 6, 1399\u20131417, https:\/\/doi.org\/10.1039\/c4fo01178c (2015).","journal-title":"Food Funct"},{"key":"33727_CR32","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s13300-017-0303-2","volume":"8","author":"FF Li","year":"2017","unstructured":"Li, F. F. et al. Effects of Vildagliptin Add-on Insulin Therapy on Nocturnal Glycemic Variations in Uncontrolled Type 2 Diabetes. Diabetes Ther 8, 1111\u20131122, https:\/\/doi.org\/10.1007\/s13300-017-0303-2 (2017).","journal-title":"Diabetes Ther"},{"key":"33727_CR33","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.vascn.2016.10.007","volume":"84","author":"S Nath","year":"2017","unstructured":"Nath, S., Ghosh, S. K. & Choudhury, Y. A murine model of type 2 diabetes mellitus developed using a combination of high fat diet and multiple low doses of streptozotocin treatment mimics the metabolic characteristics of type 2 diabetes mellitus in humans. J Pharmacol Toxicol Methods 84, 20\u201330, https:\/\/doi.org\/10.1016\/j.vascn.2016.10.007 (2017).","journal-title":"J Pharmacol Toxicol Methods"},{"key":"33727_CR34","doi-asserted-by":"publisher","first-page":"G943","DOI":"10.1152\/ajpgi.00303.2004","volume":"288","author":"X Qin","year":"2005","unstructured":"Qin, X. et al. GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats. Am J Physiol Gastrointest Liver Physiol 288, G943\u2013949, https:\/\/doi.org\/10.1152\/ajpgi.00303.2004 (2005).","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"33727_CR35","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00125-006-0340-2","volume":"49","author":"N Matikainen","year":"2006","unstructured":"Matikainen, N. et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 49, 2049\u20132057, https:\/\/doi.org\/10.1007\/s00125-006-0340-2 (2006).","journal-title":"Diabetologia"},{"key":"33727_CR36","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ijcard.2012.04.087","volume":"158","author":"S Maeda","year":"2012","unstructured":"Maeda, S., Matsui, T. & Yamagishi, S. Vildagliptin inhibits oxidative stress and vascular damage in streptozotocin-induced diabetic rats. Int J Cardiol 158, 171\u2013173, https:\/\/doi.org\/10.1016\/j.ijcard.2012.04.087 (2012).","journal-title":"Int J Cardiol"},{"key":"33727_CR37","first-page":"4560","volume":"40","author":"SX Yan","year":"2015","unstructured":"Yan, S. X., Li, X., Sun, C. D. & Chen, K. S. [Hypoglycemic and hypolipidemic effects of quercetin and its glycosides]. Zhongguo Zhong Yao Za Zhi 40, 4560\u20134567 (2015).","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"key":"33727_CR38","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/0092-8674(88)90051-7","volume":"55","author":"B Thorens","year":"1988","unstructured":"Thorens, B., Sarkar, H. K., Kaback, H. R. & Lodish, H. F. Cloning and functional expression in bacteria of a novel glucose transporter present in liver, intestine, kidney, and beta-pancreatic islet cells. Cell 55, 281\u2013290 (1988).","journal-title":"Cell"},{"key":"33727_CR39","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1039\/c3fo30389f","volume":"4","author":"CC Lee","year":"2013","unstructured":"Lee, C. C., Shen, S. R., Lai, Y. J. & Wu, S. C. Rutin and quercetin, bioactive compounds from tartary buckwheat, prevent liver inflammatory injury. Food Funct 4, 794\u2013802, https:\/\/doi.org\/10.1039\/c3fo30389f (2013).","journal-title":"Food Funct"},{"key":"33727_CR40","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/1476-511x-13-184","volume":"13","author":"IB Gomes","year":"2014","unstructured":"Gomes, I. B. et al. Renoprotective, anti-oxidative and anti-apoptotic effects of oral low-dose quercetin in the C57BL\/6J model of diabetic nephropathy. Lipids Health Dis 13, 184, https:\/\/doi.org\/10.1186\/1476-511x-13-184 (2014).","journal-title":"Lipids Health Dis"},{"key":"33727_CR41","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/jme-17-0005","volume":"59","author":"AA Hasan","year":"2017","unstructured":"Hasan, A. A. & Hocher, B. Role of soluble and membrane-bound dipeptidyl peptidase-4 in diabetic nephropathy. J Mol Endocrinol 59, R1\u2013R10, https:\/\/doi.org\/10.1530\/jme-17-0005 (2017).","journal-title":"J Mol Endocrinol"},{"key":"33727_CR42","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12933-017-0539-1","volume":"16","author":"SA Peeters","year":"2017","unstructured":"Peeters, S. A. et al. Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study. Cardiovasc Diabetol 16, 55, https:\/\/doi.org\/10.1186\/s12933-017-0539-1 (2017).","journal-title":"Cardiovasc Diabetol"},{"key":"33727_CR43","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1159\/000430266","volume":"36","author":"D Zheng","year":"2015","unstructured":"Zheng, D. et al. Exogenous Hydrogen Sulfide Attenuates Cardiac Fibrosis Through Reactive Oxygen Species Signal Pathways in Experimental Diabetes Mellitus Models. Cell Physiol Biochem 36, 917\u2013929, https:\/\/doi.org\/10.1159\/000430266 (2015).","journal-title":"Cell Physiol Biochem"},{"key":"33727_CR44","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1172\/jci29103","volume":"116","author":"M Prentki","year":"2006","unstructured":"Prentki, M. & Nolan, C. J. Islet beta cell failure in type 2 diabetes. J Clin Invest 116, 1802\u20131812, https:\/\/doi.org\/10.1172\/jci29103 (2006).","journal-title":"J Clin Invest"},{"key":"33727_CR45","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.diabres.2010.10.012","volume":"91","author":"JM Cho","year":"2011","unstructured":"Cho, J. M. et al. A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing \u03b2-cell replication and neogenesis. Diabetes Res Clin Pract 91, 72\u201379, https:\/\/doi.org\/10.1016\/j.diabres.2010.10.012 (2011).","journal-title":"Diabetes Res Clin Pract"},{"key":"33727_CR46","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s00125-016-3899-2","volume":"59","author":"B Ahren","year":"2016","unstructured":"Ahren, B. & Foley, J. E. Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism. Diabetologia 59, 907\u2013917, https:\/\/doi.org\/10.1007\/s00125-016-3899-2 (2016).","journal-title":"Diabetologia"},{"key":"33727_CR47","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/j.1464-5491.2012.03744.x","volume":"30","author":"P George","year":"2013","unstructured":"George, P. & McCrimmon, R. J. Potential role of non-insulin adjunct therapy in Type 1 diabetes. Diabet Med 30, 179\u2013188, https:\/\/doi.org\/10.1111\/j.1464-5491.2012.03744.x (2013).","journal-title":"Diabet Med"},{"key":"33727_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-11430-7","volume":"7","author":"M Hamidi Shishavan","year":"2017","unstructured":"Hamidi Shishavan, M. et al. Metformin Improves Endothelial Function and Reduces Blood Pressure in Diabetic Spontaneously Hypertensive Rats Independent from GlycemiaControl: Comparison to Vildagliptin. Scientific reports 7, 10975, https:\/\/doi.org\/10.1038\/s41598-017-11430-7 (2017).","journal-title":"Scientific reports"},{"key":"33727_CR49","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.ejps.2011.11.016","volume":"45","author":"AS Akarte","year":"2012","unstructured":"Akarte, A. S., Srinivasan, B. P. & Gandhi, S. Relationships between the islets blood flow, nitric oxide, insulin, and cytosolic calcium in rat pancreatic islets: effects of DPP-IV inhibitor vildagliptin. European journal of pharmaceutical sciences: official journal of the European Federation for Pharmaceutical Sciences 45, 546\u2013551, https:\/\/doi.org\/10.1016\/j.ejps.2011.11.016 (2012).","journal-title":"European journal of pharmaceutical sciences: official journal of the European Federation for Pharmaceutical Sciences"},{"key":"33727_CR50","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.yjmcc.2007.07.055","volume":"43","author":"MM Sung","year":"2007","unstructured":"Sung, M. M. et al. Matrix metalloproteinase-2 degrades the cytoskeletal protein alpha-actinin in peroxynitrite mediated myocardial injury. Journal of molecular and cellular cardiology 43, 429\u2013436, https:\/\/doi.org\/10.1016\/j.yjmcc.2007.07.055 (2007).","journal-title":"Journal of molecular and cellular cardiology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-33727-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-33727-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-33727-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T10:31:51Z","timestamp":1671618711000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-33727-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,17]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["33727"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-33727-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,17]]},"assertion":[{"value":"21 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"15310"}}